When your body's chemistry shifts gear

Recovery that takes longer than it used to. Joints that ache on mornings when they never did before. Sleep that fragments for no obvious reason. For many women in their early to mid-forties, these changes arrive separately — and so get addressed separately. A physio appointment for the shoulder, a GP visit for the insomnia, ibuprofen for the stiffness. What rarely gets asked is whether they share a single root.

They may well do. Oestrogen is far more than a reproductive hormone. It acts as a systemic chemical regulator — governing immune activity, pain signalling, and the neurotransmitters that anchor sleep. When this regulatory molecule begins to fluctuate during perimenopause, the downstream effects ripple across physiology simultaneously.

Surgeon and regenerative medicine specialist Professor Paul Lee frames hormones as central to what Regeneration by Design calls the Chemistry Pillar: the body's internal environment, and its capacity to repair and regulate itself. Viewed through that lens, the erratic decline of oestradiol — and its gradual replacement by oestrone, which the evidence suggests may carry more pro-inflammatory properties — is less a gynaecological event than a systems-level chemistry shift. And that framing changes which questions are worth asking.

Oestrogen as your internal anti-inflammatory

Think of oestrogen as a dimmer switch on immune reactivity. When levels are healthy, the switch holds inflammatory signals in check — calibrated, responsive, settling back to baseline once a threat passes. As oestrogen begins its perimenopausal decline, that fine control loosens.

The mechanism sits at the receptor level. Oestrogen receptor alpha (ERα — the primary receptor type involved in immune regulation) is most densely expressed on natural killer and natural killer T cells, the immune system's rapid-response units, followed by T cells. In laboratory studies, female hormones dose-dependently reduce T-cell production of GM-CSF and IFN-γ — proteins that amplify immune reactivity — indicating that oestrogen actively damps the intensity of immune signalling. A 2026 immunology study confirmed that menopausal status differentially alters how lymphoid immune cells respond to inflammatory challenge, with hormone replacement therapy partially restoring the regulation that oestrogen had previously maintained.

As for the move from oestradiol to oestrone: at the molecular level this shift may compound matters, since oestrone appears to carry more pro-inflammatory properties. Staging data on specific inflammatory markers remain limited, so the picture is mechanistically plausible rather than precisely mapped.

The practical result is a body whose inflammatory thermostat has grown less precise — lower-threshold triggers, slower resolution, and a tendency for irritation to linger where it once quickly cleared. In Professor Paul Lee's Chemistry Pillar terms, the body's internal environment has become more reactive, and that shift sets the stage for the joint and sleep changes that follow.

Why joints get louder in perimenopause

Numbers make this concrete. A 2026 meta-analysis published in the Journal of Bone and Joint Surgery pooled data from 93,021 women and found that 57% of perimenopausal women report muscle or joint pain, versus 40% in the premenopausal group — a statistically significant 1.35-fold risk increase (RR 1.35, 95% CI 1.25–1.46, p<0.001). That jump is not explained by general ageing alone; the mechanism is specific to the hormonal transition.

Two pathways account for it. The first is structural: joints carry oestrogen receptors directly, and when oestradiol falls, those receptors lose their ligand. Oestrogen's presence normally limits cartilage degradation and holds inflammatory activity within joint tissue in check; without it, inflammation rises and the risk of conditions such as osteoarthritis climbs, making movement feel more effortful.

The second pathway is neurological. G protein-coupled oestrogen receptors (GPER) in dorsal root ganglion neurons — the sensory nerve clusters that relay pain signals to the spinal cord — mediate neuronal sensitisation. A 2022 study found that inhibiting GPER expression downregulated IL-1β and IL-6, directly linking falling oestrogen to amplified nociception. The nervous system itself becomes a louder amplifier of signals that would previously have registered as minor. A controlled comparative study confirms the effect: women on hormonal supplementation show significantly higher pain tolerance than naturally cycling women (p<0.001).

Professor Paul Lee names this directly in Practical Regeneration as a Chemistry Pillar issue. Low oestrogen heightens pain receptor sensitivity — headaches, joint aches and muscle soreness all register more sharply — while removing the anti-inflammatory buffering that would otherwise speed resolution. Pain that would once have cleared in days can persist, and the body's capacity to separate a meaningful signal from background noise quietly degrades.

The broken sleep chemistry chain

The pineal gland produces melatonin from serotonin — and serotonin synthesis, in turn, depends on oestrogen. This three-step chain — oestrogen → serotonin → melatonin — means that as oestradiol falls during perimenopause, the brain's ability to generate its own sleep signal weakens at source, independent of whether a hot flush ever wakes anyone.

The consequence reaches the suprachiasmatic nucleus (SCN), the brain's master circadian pacemaker, which relies on melatonin rhythm to time sleep onset and maintain sleep architecture. Reduced melatonin blunts the SCN's signal, making sleep harder to initiate and — crucially — harder to sustain through the night.

A 2025 review in Gynecological and Clinical Obstetrics confirmed that both hot flushes and reproductive hormone changes independently predict perimenopausal sleep disruption; neither alone accounts for the full picture. That distinction matters: vasomotor symptoms are the visible, commonly cited story, but the circadian chemistry disruption is quieter and more pervasive. Research also points to progesterone's influence on sleep architecture, though the relationship is not yet precisely quantified.

Sleep disturbances affect roughly 40–60% of perimenopausal and menopausal women. A 2024 polysomnography study found that worse sleep architecture — lower sleep efficiency, reduced slow-wave sleep, higher wake-after-sleep-onset — is independently associated with elevated cortisol and a heightened cortisol awakening response, separate from subjective feelings of insomnia. That cortisol rise is the critical link to what comes next: a stress hormone that is itself pro-inflammatory and pain-sensitising, feeding back into the inflammation and joint sensitivity channels already in motion.

How the three channels feed each other

Cortisol is where the three channels stop running in parallel and start feeding each other. Elevated cortisol — a consequence of the disrupted sleep architecture described above — is itself pro-inflammatory and pain-sensitising. In Practical Regeneration, Professor Paul Lee frames this explicitly as a vicious loop: worse sleep raises cortisol, which deepens inflammation and amplifies pain, which further disrupts sleep, which raises cortisol once more. Each channel pulls on the others; there is no tidy starting point.

A downstream chemistry risk follows from that dynamic. Women managing heightened joint and muscle pain often reach for regular NSAIDs — an understandable short-term impulse, but one with an unintended cost. Professor Paul Lee cautions in Practical Regeneration that suppressing pain signals without addressing the hormonal root cause places additional stress on the gut. Oestrogen's anti-inflammatory and tissue-buffering role extends to the gut lining, so as oestradiol falls, that environment is already working under added pressure; for some women in this situation, regular NSAID use may represent an unfavourable chemistry trade-off. How to support the gut's nutritional environment instead is addressed in the next section.

This interconnection is what Regeneration by Design means when it treats Chemistry as a pillar, not a checklist: inflammation, pain and sleep chemistry share substrates and signals, and adjusting one without considering the others misses the system. Understanding the loop also reframes the reader's practical question — from which symptom do I address? to which entry point into this cycle is most accessible right now? — and that is a genuinely more useful place to start.

Practical levers for your internal environment

Given the loop just described, sleep chemistry is the most upstream entry point — and therefore the most leveraged place to start. The melatonin chain sits before the cortisol rise that feeds both inflammation and pain, which means protecting sleep architecture has wider downstream reach than addressing either of those channels directly.

In practical terms, that means treating light before food. Morning bright light — ten to twenty minutes outdoors within an hour of waking — anchors the SCN's circadian signal when endogenous melatonin is no longer reliably available. Reducing blue-spectrum light in the two hours before bed removes a competing input the SCN can no longer counteract as efficiently. A consistent wake time, even after a broken night, reinforces whatever circadian signal remains.

From there, anti-inflammatory nutrition — less ultra-processed food, more fermented foods and polyphenol-rich vegetables — directly supports the gut lining that Professor Paul Lee identifies in Practical Regeneration as already under pressure when oestrogen falls. And consistent load-bearing movement — at least three sessions a week — supports joint receptor health at the point where Chemistry and Physics genuinely overlap: mechanically loading oestrogen-receptor-bearing tissue is not just a fitness goal but a chemistry intervention.

Tracking your internal environment over time makes patterns visible. The Regen PhD ecosystem's blood panel monitoring and Digital Body Bank are designed for this — turning subjective shifts in sleep quality, pain sensitivity and energy into quantifiable signals you can act on.

If your symptoms are significantly affecting daily life, consulting a healthcare professional about hormone therapy is the right next step. This article provides context, not clinical advice.

Because cortisol is the amplifier in this loop, sleep is where designing your internal environment — in the Regeneration by Design sense — most usefully begins. Fix the upstream chemistry, and the downstream noise tends to quieten with it.

This article is for general wellness information only. It is not a substitute for personalised medical advice. Please consult a qualified healthcare professional with any health concerns.

1. [1] Musculoskeletal Manifestations of Perimenopause: A Systematic Review and Meta-Analysis of 93,021 Women. (2026). https://doi.org/10.2106/JBJS.OA.25.00254 https://doi.org/10.2106/JBJS.OA.25.00254
2. [2] Positive interaction between GPER and β-alanine in the dorsal root ganglion: mediating neuronal sensitization and neuroinflammation in neuropathic pain. (2022). https://doi.org/10.1186/s12974-022-02524-9 https://doi.org/10.1186/s12974-022-02524-9
3. [3] Sleep disturbance and menopause. (2025). https://doi.org/10.1097/GCO.0000000000001012 https://doi.org/10.1097/GCO.0000000000001012
4. [4] Worse sleep architecture but not self-reported insomnia is associated with higher cortisol levels in menopausal women. (2024). https://doi.org/10.1016/j.maturitas.2024.108053 https://doi.org/10.1016/j.maturitas.2024.108053
5. [5] Effect of hormonal supplementation on pain tolerance in women — a comparative study. (2022). https://doi.org/10.18231/j.ijcap.2022.003 https://doi.org/10.18231/j.ijcap.2022.003